Worry is a common symptom in various psychiatric problems and the key symptom of generalised anxiety disorder (GAD). The Penn State Worry Questionnaire (PSWQ) is the most widely used self-report scale for measuring worry. The present study provides normative data for the Dutch version of the PSWQ for a large community sample and a clinically referred sample of patients with GAD. Norms are not only provided for the original 16-item version, but also for an abbreviated 11-item version, which only consists of the positively worded items and has been shown to be a promising alternative to the full-length version. The percentile scores obtained for the community sample and the clinical GAD sample did not show much overlap, and this appeared true for the full-length as well as the abbreviated version of the PSWQ. These normative data seem suitable for differentiating between normal and abnormal manifestations of worrying and for evaluating the efficacy of treatments for GAD. (Netherlands Journal of Psychology, 65,(69)(70)(71)(72)(73)(74)(75) 
Worry is a common symptom in various psychiatric problems, including anxiety, mood, and eating disorders (Harvey, Watkins, Mansell, & Shafran, 2004) . In addition, excessive and uncontrollable worrying is viewed as the cardinal feature of generalised anxiety disorder (GAD; American Psychiatric Association, 2000) . To assess the frequency, intensity, and uncontrollability of worry and to evaluate the efficacy of treatments for GAD, psychometrically sound assessment tools are strongly needed, as well as representative normative data for such measures. In the case of worry and GAD, the Penn State Worry Questionnaire (PSWQ; Meyer, Miller, Metzger, & Borkovec, 1990 ) has emerged as the most widely used self-report measure, in both research and clinical practice.
The PSWQ was originally developed as a unifactorial measure, with 11 positively worded items (e.g., 'I worry about projects until they are all done') and five negatively worded items (e.g., 'I never worry about anything'). Factor analytic studies have indicated that a two-factor model (with the positively worded items loading on the first factor and the negatively worded items loading on the second factor) provided a better fit for the data than the hypothesised one-factor model (Brown, Antony, & Barlow, 1992; Stöber, 1995; Beck, Stanley, & Zebb, 1995; Van Rijsoort, Emmelkamp, & Vervaeke, 1999) . However, more recent research has shown that the negatively worded items form a method factor that should be considered a statistical artifact and is not really meaningful (Brown, 2003; Hazlett-Stevens, Ullman, & Craske, 2004 ; Van der Heiden, Muris, Bos, & Van der Molen, submitted). As such, it has been argued that the negatively worded items may undermine the psychometric qualities of the PSWQ (Woods, 2006) , and so it has been suggested to remove these items from the scale and to employ an abbreviated scale that only includes the positively worded items (HazlettStevens et al., 2004; Fresco, Heimberg, Mennin, & Turk, 2002) . There is indeed some evidence indicating that such a shortened version of the PSWQ is just as or even more reliable and valid than its full-length counterpart (Hazlett-Stevens et al., 2004; Fresco et al., 2002) .
While many studies have investigated the reliability and validity of the PSWQ (see for a review: Startup & Erickson, 2006) , research presenting normative data for this measure is sparse. So far, only one investigation has provided norms for the PSWQ in a community sample (Gillis, Haaga, & Ford, 1995) . Further, normative data in clinical populations are limited to a handful of studies that reported cut-off scores that may be helpful for discriminating GAD patients from other patient groups (Behar, Alcaine, Zuellig, & Borkovec, 2003; Fresco, Mennin, Heimberg, & Turk, 2003) . The present study was designed to provide normative data for the Dutch version of the PSWQ for a sample from the general population and a clinical sample of patients with GAD. Given its potential we also provided cut-off scores for the shortened 11-item version of the PSWQ , for which currently no normative data exist.
Method

Participants and procedure
In order to obtain a large and representative sample of the general population, we approached participants in three ways. A sample of 455 participants was drawn from the Dutch population by Flycatcher, a full-service online research company. Effort was made to match this sample to the demographic profile of the adult Dutch population. Participants completed the PSWQ as part of a larger survey in return for a small financial reward. In addition, 340 participants filled in the PSWQ , after the questionnaire had been distributed by e-mail within the personal networks of the first author and several colleagues, friends, and family, and within the networks of some of the participants themselves (i.e., snowball sampling method). Examples of networks where the PSWQ was administered were sport clubs (e.g., soccer club), church communities, and companies (e.g., cleaning company). Finally, 47 participants were approached at two shopping malls in Rotterdam, the Netherlands, with the request to complete the PSWQ. Participants in the last two groups did not receive a reward for their participation. The overall sample consisted of 842 participants (379 men and 463 women; mean age = 43.6 years, SD = 15.8; range 16-84 years), none of whom were actually being treated for a psychological disorder and thus were defined as 'non-clinical' (Kendall & Sheldrick, 2000; Sabshin, 1989) .
Participants in the clinical sample of GAD patients completed the PSWQ as part of the standard assessment at PsyQ , a mental health care organisation specialised in cognitive-behaviour therapy. The diagnosis of GAD was established using the Structured Clinical Interview for DSM-IV (SCID I: First, Spitzer, Gibbon, & Williams, 1994) , which was administered by a trained psychologist. In a second diagnostic interview, the diagnosis of GAD was confirmed by another experienced clinician. In total, 102 patients took part in this study (26 men and 76 women; mean age = 34.2 years, SD = 10.5, range 19-66 years).
Questionnaire
As already described in the introduction, the PSWQ was designed to assess the intensity, excessiveness and uncontrollability of worry (Meyer et al., 1990) . Respondents are instructed to indicate for each of the 16 items how applicable they are to them, using a five-point scale ranging from 'not at all typical of me' to 'very typical of me'. A total score is calculated by summing all items, after recoding the scores on the five negatively worded items. As such, scores range from 16 to 80, with higher scores representing a stronger tendency to worry. Psychometric properties of the original English version are good (Meyer et al., 1990) , and this is also true for the Dutch version of the scale (Kerkhof, Hermans, Figee, Laeremans, Pieters, & Aardema, 2000; Van Rijsoort, Vervaeke, & Emmelkamp, 1997; Van Rijsoort et al., 1999) . In the present study, Cronbach's alpha values for the fulllength PSWQ were 0.92 in the community sample and 0.83 in the clinical sample of GAD patients. For the shortened version these values were 0.93 and 0.87, respectively.
Results
The Statistical Package for the Social Sciences (SPSS) was used to compute mean scores, stan-dard deviations, and percentile scores (i.e., cutoff scores for 10 equal groups) for the full-length PSWQ and the abbreviated 11-item PSWQ in both the community and the clinical GAD sample.
For the full-length version of the PSWQ , the range of total scores in the non-clinical sample was 17-80 (M = 42.4, SD = 11.8), for the abbreviated PSWQ the range was 11-55 (M = 25.9, SD = 9.4). Significant sex and age differences were found for both the full-length and the abbreviated version of the PSWQ. Participants younger than 45 years (PSWQ: M = 43.1, SD = 11.8; abbreviated PSWQ: M = 26.6, SD = 9.3) displayed significantly higher PSWQ scores than participants aged 45 and above (PSWQ: M = 41.4, SD = 11.6; abbreviated PSWQ: M = 25.2, SD = 9.5) [t(840)'s being 2.08, p < 0.05 and 2.27, p < 0.05 respectively]. Further, women (PSWQ: M = 44.1, SD = 12.0; abbreviated PSWQ: M = 27.1, SD = 9.7) reported significantly higher levels of worry than men (PSWQ: M = 40.2, SD = 11.1; abbreviated PSWQ: M = 24.5, SD = 8.8) [t(840)'s being 4.89, p < 0.01 and 4.09, p < 0.01 respectively].
In the clinical sample of patients with GAD the range of total scores was 37-80 (M = 67.1, SD = 8.8) for the full-length PSWQ , and 17-55 (M = 44.9, SD = 7.8) for the abbreviated version. Here, no significant sex and age differences were found.
Percentile scores for the full-length PSWQ are presented for both the community and the clinical sample in Table 1 . Age-and sex-specific norms for the community sample are displayed in Table 2 . For the abbreviated PSWQ , these normative data are provided in Tables 3 and 4 . It is noteworthy that for both versions of the PSWQ , there was hardly any overlap in the percentile scores for the community and clinical samples (see Tables 1 and 3) . A score of 58 or 59 on the fulllength version, and a score between 35 and 39 on the abbreviated scale appeared to differentiate between the two samples, and thus seems to indicate the boundary between normal and pathological worrying. Table 1 Cut-off scores for ten equal groups of the PSWQ in a community sample (n = 842) and a sample of clinically referred GAD patients (n = 102) Table 3 Cut-off scores for ten equal groups of the abbreviated PSWQ in a community sample (n = 842) and a sample of clinically referred GAD patients (n = 102) 
Discussion
Statistical significance testing is traditionally the predominant way in research evaluating the efficacy and effectiveness of treatments for psychological disorders. While it is important to demonstrate that an intervention yields reductions in symptoms at a 'beyond chance' level, it is also essential to quantify the magnitude and meaningfulness of this improvement, which is generally referred to as 'clinical significance'. A statistically significant result could represent only modest benefits from therapy if the withingroup variability is small or the sample size is large (Gillis et al., 1995) . Therefore, methods have been developed for measuring the extent to which treatments produce clinically significant benefits. For example, Jacobson and Truax (1991) introduced the Reliable Change Index, which basically considers a patient to be 'recovered' when he/she displays improvement to a statistically reliable degree. Kendall and Grove (1988) proposed another possibility to compare data from treated individuals to normative data, typically collected from community samples. Such comparisons answer the question to what extent the treated individual, at post-treatment, is clinically equivalent to the normative group. Typically, these methods require normative data for outcome measures which possess good reliability and validity. The present study provides such normative data for the PSWQ , the most widely employed self-report scale for measuring worry, the key feature of GAD. For this purpose, the PSWQ was administered in a large community sample as well as a clinically referred sample of patients with GAD, for which currently no such normative data are available. Normative data were not only provided for the original 16-item version, but also for an abbreviated version from which the five negatively worded items have been removed. This shortened version of the PSWQ has been shown to be a promising alternative for the full-length version (Hazlett-Stevens et al., 2004; Fresco et al., 2002) , and might overcome some of the problematic aspects of the use of reversed items. That is, negatively worded items can reduce the reliability and validity of a scale, and frequently form a separate method factor that has no substantive meaning (Woods, 2006) , which was also shown to be the case with the PSWQ (Brown, 2003; Hazlett-Stevens et al., 2004; Van der Heiden et al., submitted) . Thus, for the assessment of treatment effects it seems most appropriate to employ the normative data of the abbreviated version of the PSWQ. Nevertheless, it is recommended to administer the full-length version, as the negatively worded items may be helpful to disrupt a potential response bias when completing the scale (Marsh, 1996) .
Positive features of this study are the adequate sample size of the community sample and the use of a well-diagnosed clinical sample of adult patients with GAD, the disorder for which worry is the key symptom. Furthermore, this is the first study that provides cut-off scores for the PSWQ for a clinically referred sample of patients with GAD, and the first to provide normative data for the abbreviated version of the PSWQ for both a community sample and a sample of GAD patients. Besides these strengths, a number of limitations should also be mentioned. First, the community sample may not be fully representative for the demographic profile of the adult population. Second, with the exception of the Flycatcher subsample of the community sample, we do not know the response rate in the other subsamples, so in this respect the representativeness of these populations is questionable. Nevertheless, it should be noted that the current cutoff scores of the PSWQ compare really well with those obtained in previous research (Behar et al., 2003; Fresco et al., 2003; Gillis et al., 2005) , and so it seems reasonable to conclude that the normative data as provided in the current study are suitable for identifying high worrying individuals and for interpreting treatment outcome results. Further, to assist clinicians in assessing treatment progress, on which they can base their decision to continue, adjust or terminate treatment, norm groups for both the full-length and the abbreviated PSWQ in the community sample are presented in Table 5 . Table 5 Norm groups for the full-length and the abbreviated PSWQ 
